乳腺癌TILs与新辅助疗效之间相关性研究
Research on the Correlation between TILs and Neoadjuvant Efficacy in Breast Cancer
DOI: 10.12677/ACM.2022.1281062, PDF,   
作者: 傅腾超：青岛大学，山东 青岛；赵晓辉, 牛婷婷, 吴 琍*：青岛大学附属医院，山东 青岛
关键词: 肿瘤浸润淋巴细胞；免疫微环境；疗效；Tumor Infiltrating Lymphocytes； Immune Microenvironment； Efficacy
摘要: 乳腺癌已经成为危害女性健康最常见的恶性肿瘤之一，且发病率逐年上升，严重危害女性的生命健康。乳腺癌的生存环境不仅由肿瘤细胞组成，还包括与肿瘤相互接触的细胞，这些共同构成了肿瘤微环境，在肿瘤微环境中，肿瘤浸润淋巴细胞起到了重要作用，有研究证明，TILs与新辅助化疗的疗效相关，在不同亚型当中，TILs的作用也不尽相同，研究TILs对我们预测乳腺癌患者的预后将会产生重要意义。
Abstract: Breast cancer has become one of the most common malignant tumors endangering women’s health, and the incidence is increasing year by year, seriously endangering women’s life and health. Breast cancer survival environment is not only composed of tumor cells, including the contact with tumor cells. These constitute the tumor microenvironment. In tumor microenvironment, the tumor infil-trating lymphocytes play an important role. Research has shown that TILs are associated with the curative effect of neoadjuvant chemotherapy. Among different subtypes, the role of TILs is also dif-ferent. The research of TILs is of great significance for us to predict the prognosis of breast cancer patients.
文章引用：傅腾超, 赵晓辉, 牛婷婷, 吴琍. 乳腺癌TILs与新辅助疗效之间相关性研究[J]. 临床医学进展, 2022, 12(8): 7353-7359. https://doi.org/10.12677/ACM.2022.1281062

参考文献

[1] 李宜臻, 郑怡, 邓玉皎, 等. 1990~2019中国女性乳腺癌疾病负担及危险因素研究[J]. 中国循证医学杂志, 2021, 21(8): 876-881.
[2] 赫捷, 陈万青, 李霓, 等. 中国女性乳腺癌筛查与早诊早治指南(2021, 北京) [J]. 中国肿瘤, 2021, 30(3): 161-191.
[3] Lee, K., Kruper, L., Dieli-Conwright, C.M. and Mortimer, J.E. (2019) The Impact of Obesity on Breast Cancer Diagnosis and Treatment. Current Oncology Reports, 21, Article No. 41. [Google Scholar] [CrossRef] [PubMed]
[4] de la Mare, J.A., Contu, L., Hunter, M.C., et al. (2014) Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment. Recent Patents on Anti-Cancer Drug Discovery, 9, 153-175. [Google Scholar] [CrossRef] [PubMed]
[5] Shien, T. and Iwata, H. (2020) Adjuvant and Neoadjuvant Therapy for Breast Cancer. Japanese Journal of Clinical Oncology, 50, 225-229. [Google Scholar] [CrossRef] [PubMed]
[6] Wang-Lopez, Q., Chalabi, N., Abrial, C., et al. (2015) Can Pathologic Complete Response (pCR) Be Used as a Surrogate Marker of Survival after Neoadjuvant Therapy for Breast Cancer? Critical Reviews in Oncology/Hematology, 95, 88-104.
[7] Deepak, K.G.K., Vempati, R., Nagaraju, G.P., et al. (2020) Tumor Microenvironment: Challenges and Opportunities in Targeting Metastasis of Triple Negative Breast Cancer. Pharmacological Research, 153, Article ID: 104683. [Google Scholar] [CrossRef] [PubMed]
[8] Park, S. and Yi, G. (2022) Development of Gene Expres-sion-Based Random Forest Model for Predicting Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer. Cancers, 14, 881.
[9] Salemme, V., Centonze, G., Cavallo, F., et al. (2021) The Crosstalk between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Frontiers in Oncology, 11, Article ID: 610303. [Google Scholar] [CrossRef] [PubMed]
[10] Lei, X., Lei, Y., Li, J.K., et al. (2020) Immune Cells within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy. Cancer Letters, 470, 126-133. [Google Scholar] [CrossRef] [PubMed]
[11] Savas, P., Caramia, F., Teo, Z.L. and Loi, S. (2014) Oncogene Addiction and Immunity: Clinical Implications of Tumour Infiltrating Lymphocytes in Breast Cancers Overexpressing the HER2/Neu Oncogene. Current Opinion in Oncology, 26, 562-567. [Google Scholar] [CrossRef] 
[12] Dieci, M.V., Miglietta, F. and Guarneri, V. (2021) Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. Cells, 10, 223.
[13] Gonzalez-Ericsson, P.I., Stovgaard, E.S., Sua, L.F., et al. (2020) The Path to a Better Biomarker: Application of a Risk Management Framework for the Implementation of PD-L1 and TILs as Immuno-Oncology Biomarkers in Breast Cancer Clinical Trials and Daily Practice. The Journal of Pathology, 250, 667-684. [Google Scholar] [CrossRef] [PubMed]
[14] Salgado, R., Denkert, C., Demaria, S., et al. (2015) The Evaluation of Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Recommendations by an International TILs Working Group 2014. Annals of Oncology, 26, 259-271. [Google Scholar] [CrossRef] [PubMed]
[15] Hendry, S., Salgado, R., Gevaert, T., et al. (2017) Assessing Tu-mor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointesti-nal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 24, 311-335. [Google Scholar] [CrossRef] 
[16] Romagnoli, G., Wiedermann, M., Hübner, F., et al. (2017) Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogen-icity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. International Journal of Mo-lecular Sciences, 18, Article No. 1936.
[17] Jiang, X., Xu, J., Liu, M., et al. (2019) Adoptive CD8+ T Cell Therapy against Cancer: Challenges and Opportunities. Cancer Letters, 462, 23-32. [Google Scholar] [CrossRef] [PubMed]
[18] Schmidt, M., Weyer-Elberich, V., Hengstler, J.G., et al. (2018) Prognostic Impact of CD4-Positive T Cell Subsets in Early Breast Cancer: A Study Based on the FinHer Trial Patient Population. Breast Cancer Research, 20, Article No. 15. [Google Scholar] [CrossRef] [PubMed]
[19] Jensen, M.C. (2015) Immunology. Synthetic Immunobiology Boosts the IQ of T Cells. Science, 350, 514-515. [Google Scholar] [CrossRef] [PubMed]
[20] Kobayashi, S., Watanabe, T., Suzuki, R., et al. (2016) TGF-β Induces the Differentiation of Human CXCL13-Producing CD4+ T Cells. European Journal of Immunology, 46, 360-371. [Google Scholar] [CrossRef] [PubMed]
[21] Horii, M. and Matsushita, T. (2021) Regulatory B Cells and T Cell Regulation in Cancer. Journal of Molecular Biology, 433, Article ID: 166685. [Google Scholar] [CrossRef] [PubMed]
[22] Okada, M., Chikuma, S., Kondo, T., et al. (2017) Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells. Cell Reports, 20, 1017-1028. [Google Scholar] [CrossRef] [PubMed]
[23] Huang, M., O’Shaughnessy, J., Zhao, J., et al. (2020) Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network, 18, 1096-1104. [Google Scholar] [CrossRef] [PubMed]
[24] Xia, Y., Tao, H., Hu, Y., et al. (2016) IL-2 Augments the Therapeu-tic Efficacy of Adoptively Transferred B Cells Which Directly Kill Tumor Cells via the CXCR4/CXCL12 and Perforin Pathways. Oncotarget, 7, 60461-60474. [Google Scholar] [CrossRef] [PubMed]
[25] Cabrita, R., Lauss, M., Sanna, A., et al. (2020) Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma. Nature, 577, 561-565. [Google Scholar] [CrossRef] [PubMed]
[26] Helmink, B.A., Reddy, S.M., Gao, J., et al. (2020) B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response. Nature, 577, 549-555. [Google Scholar] [CrossRef] [PubMed]
[27] Bell, D., Chomarat, P., Broyles, D., et al. (1999) In Breast Car-cinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peri-tumoral Areas. Journal of Experimental Medicine, 190, 1417-1426. [Google Scholar] [CrossRef] [PubMed]
[28] Lee, H., Lee, H.J., Song, I.H., et al. (2018) CD11c-Positive Den-dritic Cells in Triple-Negative Breast Cancer. In Vivo, 32, 1561-1569. [Google Scholar] [CrossRef] [PubMed]
[29] Gardner, A., de Mingo Pulido, Á. and Ruffell, B. (2020) Dendritic Cells and Their Role in Immunotherapy. Frontiers in Immunology, 11, Article No. 924. [Google Scholar] [CrossRef] [PubMed]
[30] Nelson, M.A., Ngamcherdtrakul, W., Luoh, S.W. and Yantasee, W. (2021) Prognostic and Therapeutic Role of Tumor-Infiltrating Lymphocyte Subtypes in Breast Cancer. Cancer and Metastasis Reviews, 40, 519-536. [Google Scholar] [CrossRef] [PubMed]
[31] Laenkholm, A.V., Callagy, G., Balancin, M., et al. (2022) In-corporation of TILs in Daily Breast Cancer Care: How Much Evidence Can We Bear? Virchows Archiv, 480, 147-162.
[32] Denkert, C., Loibl, S., Noske, A., et al. (2010) Tumor-Associated Lymphocytes as an Independent Pre-dictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clinical Oncology, 28, 105-113. [Google Scholar] [CrossRef] 
[33] Cortazar, P., Zhang, L., Untch, M., et al. (2014) Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. The Lancet, 384, 164-172. [Google Scholar] [CrossRef] 
[34] Loi, S., Drubay, D., Adams, S., et al. (2019) Tu-mor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 37, 559-569. [Google Scholar] [CrossRef] 
[35] Stanton, S.E. and Disis, M.L. (2016) Clinical Significance of Tu-mor-Infiltrating Lymphocytes in Breast Cancer. Journal for ImmunoTherapy of Cancer, 4, Article No. 59. [Google Scholar] [CrossRef] [PubMed]
[36] Romero-Cordoba, S., Meneghini, E., Sant, M., et al. (2019) De-coding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation. Can-cers, 11, 911.
[37] Criscitiello, C., et al. (2020) Tumor-Infiltrating Lymphocytes (TILs) in ER+/HER2-Breast Cancer. Breast Cancer Research and Treatment, 183, 347-354. [Google Scholar] [CrossRef] [PubMed]
[38] Sobral-Leite, M., et al. (2019) Cancer-Immune Interactions in ER-Positive Breast Cancers: PI3K Pathway Alterations and Tumor-Infiltrating Lymphocytes. Breast Cancer Research, 21, Article No. 90. [Google Scholar] [CrossRef] [PubMed]
[39] Pellegrino, B., Hlavata, Z., Migali, C., et al. (2021) Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Molecular Diagnosis & Therapy, 25, 409-424. [Google Scholar] [CrossRef] [PubMed]
[40] Colombo, N., Sessa, C., du Bois, A., et al. (2019) ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease. Annals of Oncology, 30, 672-705. [Google Scholar] [CrossRef] [PubMed]

为你推荐